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linical and Angiographic Outcome
fter Implantation of Drug-Eluting Stents in
ifurcation Lesions With the Crush Stent Technique
mportance of Final Kissing Balloon Post-Dilation
ei Ge, MD,*† Flavio Airoldi, MD,* Ioannis Iakovou, MD,* John Cosgrave, MD,* Iassen Michev, MD,*
iuseppe M. Sangiorgi, MD,* Matteo Montorfano, MD,* Alaide Chieffo, MD,* Mauro Carlino, MD,*
icola Corvaja, MD,* Antonio Colombo, MD, FACC*
ilan, Italy; and Shanghai, China
OBJECTIVES The purpose of this research was to evaluate the long-term outcomes after implantation of
drug-eluting stents (DES) in bifurcation lesions with the “crush” technique.
BACKGROUND The long-term outcome of “crush” stenting technique has yet to be determined.
METHODS We identified 181 consecutive patients who were treated with DES with the “crush” stent
technique from April 2002 to April 2004. Based on the usage of final kissing balloon
post-dilation (FKB), the patients were divided into an FKB group (n 116) and a non-FKB
group (n  65).
RESULTS Clinical follow-up at nine months was available in all patients, and angiographic follow-up in
80% of patients. Three cases (1.7%) of intraprocedural stent thrombosis and five (2.8%) cases
of postprocedural stent thrombosis occurred. Restenosis rate of the main branch in the entire
cohort lesions was 11.5%. Restenosis rate of the side branch was lower in the FKB group than
that in the non-FKB group (11.1% vs. 37.9%, p  0.001). The target lesion revascularization
(TLR) rate for all patients was 14.9%. The lack of FKB was a predictor for TLR (hazard ratio
[HR] 4.17; 95% confidence interval [CI] 1.30 to 14.3, p  0.02). Diabetes was also a
predictor for TLR (HR 1.79; 95% CI 1.14 to 2.80, p  0.01). Premature discontinuation of
dual antiplatelet therapy (odds ratio [OR] 16.8; 95% CI 1.31 to 159.5, p 0.03) and age (OR
1.10; 95% CI 1.00 to 1.21, p  0.048) was associated with the occurrence of postprocedural
stent thrombosis.
CONCLUSIONS Compared to the absence of FKB, the “crush” stenting technique with FKB appears to be
associated with more favorable long-term outcomes. When utilizing the “crush” stenting
technique, FKB is mandatory. (J Am Coll Cardiol 2005;46:613–20) © 2005 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.05.032American College of Cardiology Foundation
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tmplantation of one stent in the main branch with balloon
ilation of the side branch seems to be the best approach for
reatment of most coronary bifurcation lesions with bare-
etal stents or drug-eluting stents (DES) (1,2). A limita-
ion of this approach is that some bifurcation lesions have
xtensive disease in the side branch requiring stenting of this
essel as well. “Crush” stenting technique has been proposed
s a method to implant two DES in a bifurcation with the
ntent to ensure optimal stent coverage and drug delivery to
he ostium of the side branch. Despite the fact that
hort-term outcomes of “crush” stenting are encouraging
3), the mid- or long-term outcomes of this technique
emain uncertain. The aim of this study was to evaluate the
ong-term outcomes after implantation of either sirolimus-
luting stents (SES) (Cypher, Cordis/Johnson & Johnson,
arren, New Jersey) or paclitaxel-eluting stents (PES)
From the *EMO Centro Cuore Columbus and San Raffaele Hospital, Milan, Italy;
nd †Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai,
hina. The first two authors contributed equally to this work.p
Manuscript received January 13, 2005; revised manuscript received March 2, 2005,
ccepted March 10, 2005.Taxus, Boston Scientific, Natick, Massachusetts) in bifur-
ation lesions with the “crush” stenting technique.
ETHODS
tudy population. Demographic and procedural data re-
arding all patients undergoing angioplasty at EMO Centro
uore Columbus and San Raffaele Hospital were prospec-
ively entered into a dedicated database. All consecutive
atients treated with either SES or PES by the “crush”
tenting technique between April 2002 and April 2004 were
dentified. Based on the usage of final kissing balloon
ost-dilation (FKB), the entire cohort was divided into
KB group and non-FKB group. Patients with revascular-
zation in the setting of acute myocardial infarction (AMI)
ere not considered in this report because we do not
mplant DES in these patients.
rocedures and postintervention medications. All pa-
ients were pretreated with aspirin and either ticlopidine or
lopidogrel. A 300-mg loading dose of clopidogrel before
he index procedure was administered if patients were not
retreated. During the procedure, patients received intrave-
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Long-Term Outcome of “Crush” Stenting Technique August 16, 2005:613–20ous unfractionated heparin (100 IU/kg) to maintain acti-
ated clotting time between 250 to 300 s. The administra-
ion of glycoprotein IIb/IIIa inhibitors was left to the
perator’s discretion. All patients were on maintenance
spirin therapy and clopidogrel or ticlopidine continued for
t least six months after DES implantation.
The “crush” technique has been previously described (3).
n patients who underwent FKB, wire recrossing into the
ide branch followed by high-pressure balloon inflation (12
o 14 atm) was always performed before FKB. A floppy wire
r an intermediate wire or occasionally a hydrophilic wire
Pilot 150, Guidant, Temecula, California) was chosen to
ecross into the side branch.
linical definitions and follow-up. Clinical follow-up
as performed by telephone contact or office visit at nine
onths for both groups. Angiographic follow-up was
cheduled for between six and eight months after the
rocedure unless clinically indicated earlier.
Major adverse cardiac events (MACE) were defined as
ardiac death, AMI, and target vessel revascularization
TVR), either percutaneous or surgical. Cumulative MACE
ere defined as the in-hospital and nine-month follow-up
ACE. All deaths were considered cardiac unless other-
ise documented. A non–Q-wave AMI was defined as
reatine kinase-MB enzyme elevation 3 times the upper
imit of the normal value; when in addition to enzyme
levation there were new pathological Q waves in the
lectrocardiogram, the event was defined as a Q-wave AMI.
arget lesion revascularization (TLR) was defined as a
epeat revascularization with a stenosis 50% within the
tent or in the 5-mm distal or proximal segments adjacent to
he stent; TVR was defined as repeat revascularization
ithin the treated vessel.
Stent thrombosis was defined as an acute coronary syn-
rome with angiographic documentation of either vessel
cclusion or thrombus within or adjacent to a previously
uccessfully stented vessel or, in the absence of angiographic
onfirmation, either AMI in the distribution of the treated
essel or death not clearly attributable to other causes (4).
tent thromboses were categorized according to the timing
f the event into: intraprocedural, subacute thrombosis
from the end of the procedure to 30 days), and late stent
Abbreviations and Acronyms
AMI  acute myocardial infarction
CI  confidence interval
DES  drug-eluting stent
FKB  final kissing balloon after dilation
HR  hazard ratio
MACE  major adverse cardiac events
OR  odds ratio
PES  paclitaxel-eluting stent
SES  sirolimus-eluting stent
TLR  target lesion revascularization
TVR  target vessel revascularizationhrombosis (30 days). guantitative coronary angiographic analysis. Cineangio-
rams were analyzed using a validated edge detection system
CMS, version 5.2, MEDIS, Leiden, the Netherlands) in
ain branch and in side branch. When analyzing left main
ifurcations, the main branch was the distal left main
ontinuing into the left anterior descending. Angiographic
estenosis was defined as diameter stenosis 50% within a
reviously stented segment (stent and 5 mm proximal and
istal) at the follow-up angiogram. Angiographic success
as defined as a final residual stenosis 30% with Throm-
olysis In Myocardial infarction flow grade 3 in either the
ain branch or the side branch (5). Procedural success was
efined as the achievement of angiographic success without
n-hospital MACE.
tatistical analysis. Continuous variables are presented as
ean  SD and categorical variables as frequency (%).
ontinuous variables were compared using independent
ample t test. Categorical variables were compared with
hi-square statistics or Fisher exact test. Fisher exact test
as used when any expected cell count was 5 (not
esulting from missing rows or columns in a larger table).
ecause of a low number of thrombotic events, exact logistic
egression models (6) based on permutation resampling
ere used to determine the association of postprocedural
tent thrombosis with several clinical variables (7). The
ollowing clinical variables were entered into this analysis
odel: age, gender, diabetes, ejection fraction, stent type,
nstable angina, premature discontinuation antiplatelet
herapy, left main bifurcation, the lack of use of glycoprotein
Ib/IIIa inhibitors, FKB, calcific lesions, reference vessel
iameter, lesion length, minimal lumen diameter at baseline
nd at postprocedure, balloon size, maximal balloon pres-
ure, and stent length. The results are presented as odds
atios (OR) with exact 95% confidence interval (CI) and
xact p values. Survival free of TLR was estimated using the
aplan-Meier method, and the differences between the two
urvival curves were compared with the log-rank test. The
ox regression model was used to identify the predictors of
LR at nine months. The results are presented as hazard
atios (HR) with exact 95% CI. A p value of 0.05 was
onsidered to be statistically significant, and all reported p
alues are two-sided. Analysis was performed with SAS
ersion 8.2 (SAS Inc., Cary, North Carolina).
ESULTS
aseline and procedural characteristics. A total of 181
onsecutive patients undergoing angioplasty with DES by
he “crush” stenting technique were identified (SES were
mplanted in 106 patients with 110 bifurcations and PES in
5 patients with 75 bifurcations). Of them, 116 patients
with 118 bifurcations) were included in the FKB group and
5 patients (with 67 bifurcations) in the non-FKB group.
he baseline clinical, lesion, and procedural characteristics
re shown in Tables 1, 2, and 3. Compared to the non-FKB
roup, the FKB group had a larger maximum balloon
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nd shorter stent length (26.8  8.0 mm vs. 32.5  12.8
m, p  0.001) in the main branch.
uantitative angiographic analysis. Serial quantitative
oronary angiography analysis results for the main branch
nd side branch are shown in Tables 4 and 5. Angiographic
ollow-up was available in 145 (80.1%) patients (with 148
ifurcations) at a mean period of 7.6 2.8 months after the
ndex procedure. Of these, 87 (75.0%) patients (with 90
ifurcations) were in the FKB group and 58 (89.2%)
atients (with 58 bifurcations) in the non-FKB group. Late
umen loss in the side branch was lower in the FKB group
han that in the non-FKB group (0.32  0.16 mm vs. 0.52
0.38 mm, p  0.04), resulting in a lower incidence of
estenosis (11.1% vs. 37.9%, p 0.001) (Fig. 1). Among the
2 restenotic lesions at the side branch, 24 (75.0%) were
ocal (10 mm) restenosis and located at the ostium of the
ide branch.
Table 1. Baseline Clinical Characteristics
Entire Cohort
n  181 Patients
Age, yrs 62  11
Male, n (%) 158 (87.3)
Current smoker, n (%) 31 (17.1)
Hypercholesterolemia, n (%) 130 (71.8)
Hypertension, n (%) 108 (59.7)
Diabetes mellitus, n (%) 40 (22.1)
Prior MI, n (%) 76 (42.5)
Prior PCI, n (%) 60 (33.1)
Prior CABG, n (%) 35 (19.3)
Unstable angina, n (%) 46 (25.4)
GP IIb/IIIa inhibitors, n (%) 71 (39.2)
LVEF, % 52.0  9.5
Values are presented as numbers (%) or mean  SD. *FKB
CABG  coronary artery bypass graft surgery; FKB  fin
ventricular ejection fraction; MI  myocardial infarction; PC
Table 2. Baseline Lesion Characteristics
Entire Cohort
n  185 Lesions
Calcification
Main branch 31 (16.8)
Side branch 19 (10.3)
Total occlusion
Main branch 16 (8.6)
Side branch 19 (10.3)
Restenotic lesions
Main branch 13 (7.0)
Side branch 12 (6.5)
Lesions location, n (%)
LM 49 (26.5)
LAD/diagonal 83 (44.9)
LAD/septal 1 (0.5)
LCX/OM 40 (21.6)
RCA/RCA-PL/RCA-PD 12 (6.5)
Values are presented as numbers (%). Calcification was defi
moderate when visible only during the cardiac cycle or severeFKB  final kissing balloon after dilation; LAD  left anterior
main; OM  obtuse marginal; PD  posterior descending; PL linical outcomes. In-hospital results and clinical follow-up
utcomes are shown in Table 6. There were three (1.7%)
ases of intraprocedural stent thrombosis (two in the FKB
roup treated with SES, one in the non-FKB group treated
ith PES); two of these developed non–Q-wave AMI. All
ntraprocedural stent thrombosis occurred before perform-
ng FKB. The mean total stent length of these three cases
as 69 mm, and no elective glycoprotein IIb/IIIa inhib-
tors were given. One patient treated with SES developed
Q-wave AMI in-hospital due to the occlusion of septal
ranches during the index procedure. Clinical follow-up
t nine months was available in all patients. Compared to
he non-FKB group, the rate of cumulative MACE was
ower in the FKB group (19.8% vs. 38.5%, p  0.008).
urvival free from TLR was 90.5% in the FKB group and
5.4% in the non-FKB group (p  0.008) (Fig. 2).
During clinical follow-up, five (2.8%) cases of stent
hrombosis were recorded, two (1.9%) of these treated with
FKB Group
n  116 Patients
Non-FKB Group
n  65 Patients p*
62  12 62  11 0.82
102 (87.9) 56 (86.2) 0.82
20 (17.2) 11 (16.9) 0.88
81 (69.8) 49 (75.4) 0.49
67 (57.8) 41 (63.1) 0.53
25 (21.6) 15 (23.1) 0.96
51 (44.7) 25 (38.5) 0.44
42 (36.2) 18 (27.7) 0.26
24 (20.7) 11 (16.9) 0.70
31 (26.7) 15 (23.1) 0.72
48 (41.4) 23 (35.4) 0.53
51.7  10.3 52.6  7.9 0.56
versus non-FKB group.
ing balloon after dilation; GP  glycoprotein; LVEF  left
ercutaneous coronary intervention.
FKB Group
n  118 Lesions
Non-FKB Group
n  67 Lesions p*
24 (20.3) 7 (10.4) 0.13
15 (12.7) 4 (6.0) 0.23
8 (6.8) 8 (11.9) 0.28
10 (8.5) 9 (13.4) 0.32
11 (9.3) 2 (3.0) 0.14
10 (8.5) 2 (3.0) 0.22
38 (32.2) 11 (16.4) 0.03
51 (43.2) 32 (47.8) 0.66
0 1 (1.5) 0.77
26 (22.0) 14 (20.9) 0.99
3 (2.5) 9 (13.4) 0.01
a radiopaque area found before contrast injection and was
ble also on still frames. *FKB group versus non-FKB group.groupned as
if visidescending artery; LCX  left circumflex artery; LM  left
posterior lateral; RCA  right coronary artery.
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atients had clinical events, and two patients died. The
ean age of these five patients was 72 years compared to 62
ears in the other patients (p  0.06). There were eight
atients who stopped dual antiplatelet therapy prematurely.
f these, two (25%) patients suffered thrombotic events
resenting as AMI within 7 and 10 days after stopping
spirin and clopidogrel (one due to pancreatitis, the other
ue to abdominal surgery), respectively. In the remaining
atients who continued taking dual antiplatelet therapy,
here were three (1.7%) episodes of stent thrombosis (1.7%
s. 25%, p  0.005, Fisher exact test). The incidence of
ostprocedural stent thrombosis was not statistically signif-
cantly different between the FKB group and the non-FKB
roup (2.6% vs. 3.1%, p  0.78, Fisher exact test).
redictors of TLR and stent thrombosis. The absence of
KB (HR 4.17; 95% CI 1.30 to 14.3, p  0.02) was a
redictor of TLR. Diabetes (HR 1.79; 95% CI 1.14 to 2.80,
 0.01) was also identified as a predictor of TLR.
remature discontinuation of dual antiplatelet therapy (OR
Table 3. Procedural Characteristics
Entire Cohor
n  185 Lesio
Adjunctive debulking, n (%)
Main branch 5 (2.7)
Side branch 1 (0.5)
Mean stent length, mm
Main branch 28.9  10.4
Side branch 24.7  8.4
Maximal inflation pressure, atm
Main branch 15.6  3.1
Side branch 14.5  2.8
Maximum balloon diameter, mm
Main branch 3.19  0.38
Side branch 2.85  0.40
Values are presented as numbers (%) or mean  SD. *FKB
FKB  final kissing balloon after dilation.
Table 4. Quantitative Coronary Angiography A
Entire Cohort
n  185 Lesions
Baseline
RVD, mm 2.81  0.58
MLD, mm 0.95  0.51
Diameter stenosis, % 66.3  16.6
Mean lesion length, mm 15.9  8.7
After procedure
RVD, mm 3.36  0.53
MLD, mm 2.92  0.54
Diameter stenosis, % 11.9  7.9
Acute gain, mm 1.98  0.59
Follow-up
RVD, mm 3.28  0.59
MLD, mm 2.57  0.96
Diameter stenosis, % 23.3  23.8
Mean lesion length, mm 7.8  6.6
Late lumen loss, mm 0.27  0.18
Restenosis, n (%) 17/148 (11.5)Values are presented as numbers (%) or mean  SD. *FKB group
FKB  final kissing balloon after dilation; MLD  minimal lu6.8; 95% CI 1.31 to 159.5, p  0.03) and age (OR 1.10;
5% CI 1.00 to 1.21, p  0.048) were associated with the
ccurrence of postprocedural stent thrombosis.
ISCUSSION
he main findings of this report are: 1) compared to the
bsence of FKB, the “crush” stenting with FKB appears to
e associated with a lower rate of restenosis in side branch,
nd low rates of MACE and need for revascularization; the
bsence of FKB was identified as one of the predictor factors
f TLR; and 2) the incidence of postprocedrual stent
hrombosis during nine months follow-up was 2.8%. Pre-
ature discontinuation of dual antiplatelet therapy was
trongly associated with the occurrence of postprocedural
tent thrombosis.
ull coverage of the ostium of the side branch and
KB. In the randomized SES bifurcation study (2), the
ate of restenosis in the side branch was 21.8%. Incomplete
overage of the side branch was advocated as a possible
FKB Group
n  118 Lesions
Non-FKB Group
n  67 Lesions p*
2 (1.7) 3 (4.5) 0.35
0 1 (1.5) 0.36
26.8  8.0 32.5  12.8 0.001
24.1  7.3 25.6  10.0 0.23
16.2  2.3 15.1  3.4 0.06
14.4  2.9 14.9  2.7 0.2
3.25  0.37 3.06  0.39 0.01
2.89  0.39 2.80  0.42 0.17
versus non-FKB group.
sis for the Main Branch
FKB Group
 118 Lesions
Non-FKB Group
n  67 Lesions p*
2.85  0.60 2.74  0.53 0.23
0.95  0.51 0.95  0.52 0.97
67.0  15.9 65.2  17.6 0.49
14.5  7.2 16.4  10.3 0.14
3.44  0.56 3.23  0.47 0.01
3.04  0.54 2.80  0.50 0.03
11.1  8.1 13.1  7.5 0.11
2.07  0.58 1.85  0.60 0.02
3.37  0.58 3.21  0.61 0.11
2.78  0.85 2.48  0.92 0.04
19.1  20.8 22.5  23.5 0.38
7.8  6.6 7.8  6.6 0.97
0.21  0.26 0.34  0.10 0.10
8/90 (8.9) 9/58 (15.5) 0.33t
nsnaly
nversus non-FKB group.
men diameter; RVD  reference vessel diameter.
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ull coverage of the ostium of the side branch, the “crush”
tent technique was introduced (3). Our preliminary expe-
ience with the “crush” stenting technique did not show a
lear improvement in the rate of restenosis at the side
ranch. At that time FKB was not performed routinely
hen no residual stenosis was observed at ostium of the side
Table 5. Quantitative Coronary Angiography A
Entire Cohort
n  185 Lesions
Baseline
RVD, mm 2.44  0.58
MLD, mm 0.87  0.51
Diameter stenosis, % 64.1  19.5
Mean lesion length, mm 10.9  6.7
After procedure
RVD, mm 2.87  0.46
MLD, mm 2.46  0.46
Diameter stenosis, % 14.2  9.5
Acute gain, mm 1.58  0.65
Follow-up
RVD, mm 2.84  0.52
MLD, mm 1.98  0.88
Diameter stenosis, % 30.7  27.1
Mean lesion length, mm 6.3  3.9
Late lumen loss, mm 0.40  0.27
Restenosis, n (%) 32/148 (21.6)
Values are presented as numbers (%) or mean  SD. *FKB
Abbreviations as in Table 4.igure 1. Restenosis rate and late lumen loss of drug-eluting stent implantatio
ithout kissing balloon after dilation; open bars  kissing balloon after dilatioranch. Learning from follow-up results led to more fre-
uent performance of FKB. Since January 2003, kissing
nflation became standard procedure. In the present study,
he restenosis rate of the side branch in the FKB group was
1.1%. Compared to the SES bifurcation study, a 49%
elative reduction in the restenosis rate in the side branch
as achieved (2). The significant reduction of late loss in the
sis for Side Branch
FKB Group
 118 Lesions
Non-FKB Group
n  67 Lesions p*
2.46  0.61 2.40  0.52 0.54
0.87  0.51 0.88  0.52 0.84
64.1  19.6 63.9  19.4 0.96
10.5  6.8 11.4  6.5 0.39
2.89  0.45 2.84  0.48 0.44
2.54  0.47 2.33  0.40 0.004
12.3  9.2 17.1  9.4 0.001
1.67  0.64 1.44  0.64 0.03
2.88  0.53 2.77  0.48 0.20
2.22  0.77 1.70  0.91 0.001
23.5  22.0 37.9  32.2 0.004
6.1  4.2 6.5  3.5 0.60
0.32  0.16 0.52  0.38 0.04
10/90 (11.1) 22/58 (37.9) 0.001
versus non-FKB group.naly
nn in bifurcation lesions with the “crush” stent technique. Black bars 
n.
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Long-Term Outcome of “Crush” Stenting Technique August 16, 2005:613–20ide branch after FKB can be explained by better strut
ontact to the vessel wall and better drug delivery. The
umerical and not significant reduction of late loss in the
ain branch with FKB could just be a consequence of a
ower tissue growth at the ostium of the side branch with a
ower chance to extend into the main branch (9). Stent
nderexpansion is one of the major reasons for restenosis
10), even in the DES era (11,12); FKB may correct stent
eformation and ensure optimal stent scaffolding (9,13). To
uarantee full stent strut expansion, we always performed
alloon inflation in the side branch at high pressure (12 to
4 atm) before FKB. We think that this “two-step proce-
Table 6. Clinical Outcomes
Entire C
n  181 P
Angiographic success, n (%) 178 (9
Procedural success, n (%) 162 (8
In-hospital MACE, n (%) 16 (8
Cardiac death 0
Q-wave MI 1 (0
Non–Q-wave MI 15 (8
TLR 0
TVR 0
Cumulative nine-month MACE, n (%) 48 (2
Cardiac death 2 (1
Q-wave MI 6 (3
Non–Q-wave MI 15 (8
TLR 27 (1
TVR 31 (1
Postprocedural stent thrombosis 5 (2
Subacute 1 (0
Late 4 (2
Values are presented as numbers (%). *FKB group versus no
MACE  major adverse cardiac events; TLR  target les
abbreviations as in Table 1.c
igure 2. Kaplan-Meier curve of survival free from target lesion revascu-
arization (TLR) during nine-month follow-up.ure” is essential to ensure full strut apposition at the ostium
f the side branch (14).
Similar to the findings of the SES bifurcation study (2),
he 24 (75.0%) restenosis cases of the side branch observed
n the present report were focal. However, it is important to
ention that among these 24 restenotic lesions, only 8
33.3%) lesions underwent FKB. An intriguing and unan-
wered question is why, despite apparent full coverage of the
stium of the side branch and despite performing FKB, a
ouble digit restenosis rate at the ostium of the side branch
till occurred. Possible explanations could be the breakage of
he polymer secondary to the overlap of multiple struts
ayers and uneven distribution of the stent struts at the
stium of the side branch (9). To resolve this problem,
pecific stent designs addressing the proper coverage of the
stium of the side branch may be needed.
tent thrombosis. The 1.7% incidence of intraprocedural
tent thrombosis in the present report was higher than the
ne that we reported earlier (0.7%) (7). It is important to
ote that three patients who developed intraprocedural stent
hrombosis were not treated with glycoprotein IIb/IIIa
nhibitors. In order to reduce the incidence of acute stent
hrombosis, we should consider a more liberal usage of
lycoprotein IIb/IIIa inhibitors and a more aggressive usage
f loading dose clopidogrel (15–17).
The 2.8% incidence of postprocedural stent thrombosis is
lso different from the findings of the corresponding trials
or DES in selected lesions (0.4% for SES and 0.6% for
ES) (4,18). It is also important to mention that, in the
resent study, there was a 1.7% incidence of postprocedural
tent thrombosis in patients who did not discontinue dual
ntiplatelet therapy. This finding is similar to the result of a
ecently published study, in which the incidence of postpro-
t
ts
FKB Group
n  116 Patients
Non-FKB Group
n  65 Patients p*
116 (100) 62 (95.4) 0.13
106 (91.4) 56 (86.2) 0.40
10 (8.6) 6 (9.2) 1.0
0 0 —
0 1 (1.5) 0.77
10 (8.6) 5 (7.7) 0.95
0 0 —
0 0 —
23 (19.8) 25 (38.5) 0.008
2 (1.7) 0 0.54
2 (1.7) 4 (6.2) 0.28
10 (8.6) 5 (7.7) 0.95
11 (9.5) 16 (24.6) 0.008
12 (10.3) 19 (29.2) 0.002
3 (2.6) 2 (3.1) 0.78
0 1 (1.5) 0.77
3 (2.6) 1 (1.5) 0.95
group.
vascularization; TVR  target vessel revascularization; otherohor
atien
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our-fold increase in the incidence of late stent thrombosis
n the patients treated with PES compared to the ones
reated with SES (0.9% [1 of 106] vs. 4.0% [3 of 75], p 
.39, Fisher exact test); the small number of patients should
revent us from drawing premature conclusions. Recently,
ate stent thrombosis after PES and SES implantation were
eported (20). All these data seem to point out that, when
wo DES are implanted in a bifurcation, there is a higher
isk of stent thrombosis and a strong need to adhere to dual
ntiplatelet therapy for a currently “unknown” time period.
By exact logistic regression analysis, the strongest predic-
or of postprocedural stent thrombosis was premature dis-
ontinuation of antiplatelet therapy. Recently, one study
howed that premature discontinuation of dual antiplatelet
herapy was associated with an approximately 30-fold
reater risk of stent thrombosis (19). In accordance with the
nding of another study, age was also identified as a
ignificant predictor of stent thrombosis (21).
tudy limitations. The main limitations of the present
eport are its nonrandomized design with lack of compari-
on with alternative strategies such as the implantation of a
ingle stent in the main branch, a strategy that is viewed as
default approach no matter how severe the disease in the
ide branch (22). The lack of randomization between FKB
nd non-FKB constitutes another limitation. It is of impor-
ance to mention that, in the present study, the definition of
ate stent thrombosis did not require angiographic docu-
entation; therefore, we cannot exclude that the incidence
as slightly inflated.
onclusions. Compared to the absence of kissing balloon
fter dilation, the “crush” stenting with kissing balloon after
ilation appears to be associated with more favorable long-
erm outcomes. When utilizing the “crush” stenting tech-
ique, kissing balloon after dilation is mandatory to reduce
he restenosis rate of side branch and the need for TLR.
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able 7. Clinical Characteristics and Outcomes of Patients With
Patient
Stent
Type
Age,
yrs
Time of Stent
Thrombosis,
Days Location Diabe
1 SES 80 28 LAD/diagonal Yes
2 SES 82 55 LM Yes
3 PES 71 103 LM No
4 PES 61 64 LM No
5 PES 65 90 LAD/diagonal Yes
ime of stent thrombosis: from the index procedure to the day stent thrombosis occ
AMI  acute myocardial infarction; LVEF  left ventricular ejection fraction; PESilan, Italy. E-mail: info@emocolumbus.it.EFERENCES
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